drugset
drugset / Trial / NCT03452930

Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma

NCT03452930 ↗

Phase 1 Completed 5 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This phase I trial studies the side effects and best dose of tinostamustine (EDO-S101) given with or without radiation therapy in treating patients with newly diagnosed MGMT-unmethylated glioblastoma. Tinostamustine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth in patients with glioblastoma.

Timeline

Start
2018-08-13
Primary completion
2024-06-05
Completion
2024-06-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Tinostamustine Other / unclassified — Intravenous

Indications

gliosarcoma